KEYTRUDA® (pembrolizumab) in metastatic Colorectal Cancer (CRC)

Prescribing Information

KEYTRUDA as monotherapy is indicated for:

Metastatic Colorectal Cancer
For use in The first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults1
Dosing schedule The recommended dose is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes1
Duration of treatment Treat until disease progression or unacceptable toxicity1
Clinical trial KEYNOTE-177 was a phase 3, multicenter, open-label, active-controlled study of adult patients with metastatic MSI-H/dMMR colorectal cancer, randomised 1:1 to receive pembrolizumab or investigator's choice of chemotherapy regimens2

Click here to download the KEYNOTE-177 clinical data presentation

Download

Metastatic Colorectal Cancer
For use in The first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults1
Dosing schedule The recommended dose is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes1
Duration of treatment Treat until disease progression or unacceptable toxicity1
Clinical trial KEYNOTE-177 was a phase 3, multicenter, open-label, active-controlled study of adult patients with metastatic MSI-H/dMMR colorectal cancer, randomised 1:1 to receive pembrolizumab or investigator's choice of chemotherapy regimens2

Click here to download the KEYNOTE-177 clinical data presentation

Download

References

  1. KEYTRUDA Summary of Product Characteristics.
  2. André T, Shiu K-K, Kim TW, et al. N Engl J Med. 2020; 383:2207-2218.

Supporting documentation

GB-OVA-00006 | Date of Preparation: April 2021